Stryker Co. (NYSE:SYK) Receives Average Rating of “Moderate Buy” from Analysts

Stryker Co. (NYSE:SYK) has received an average rating of “Moderate Buy” from the eighteen brokerages that are presently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and fifteen have given a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $370.50.

Several research firms recently commented on SYK. Piper Sandler raised their price objective on shares of Stryker from $375.00 to $380.00 and gave the stock an “overweight” rating in a report on Wednesday, May 1st. Truist Financial increased their target price on shares of Stryker from $330.00 to $345.00 and gave the stock a “hold” rating in a research note on Wednesday, January 31st. Stifel Nicolaus increased their target price on shares of Stryker from $350.00 to $375.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. Citigroup increased their target price on shares of Stryker from $362.00 to $406.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Finally, Roth Mkm increased their target price on shares of Stryker from $348.00 to $405.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st.

Stryker Stock Up 1.6 %

Stryker stock opened at $335.54 on Friday. Stryker has a twelve month low of $249.98 and a twelve month high of $361.41. The firm has a 50 day moving average price of $339.85 and a 200-day moving average price of $323.83. The company has a market capitalization of $127.82 billion, a P/E ratio of 38.30, a P/E/G ratio of 2.64 and a beta of 0.91. The company has a quick ratio of 0.99, a current ratio of 1.71 and a debt-to-equity ratio of 0.56.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, April 30th. The medical technology company reported $2.50 EPS for the quarter, topping the consensus estimate of $2.36 by $0.14. The company had revenue of $5.24 billion during the quarter, compared to the consensus estimate of $5.10 billion. Stryker had a net margin of 16.03% and a return on equity of 23.05%. Stryker’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same period last year, the firm earned $2.14 EPS. As a group, equities analysts predict that Stryker will post 11.95 EPS for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Investors of record on Friday, June 28th will be issued a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a dividend yield of 0.95%. The ex-dividend date of this dividend is Friday, June 28th. Stryker’s dividend payout ratio is currently 36.53%.

Insider Activity at Stryker

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the firm’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total value of $2,756,711.20. Following the sale, the chief accounting officer now owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 5.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Stryker

A number of large investors have recently added to or reduced their stakes in SYK. AIA Group Ltd bought a new stake in shares of Stryker during the 3rd quarter valued at about $316,000. Banque Pictet & Cie SA boosted its stake in shares of Stryker by 19.3% during the 3rd quarter. Banque Pictet & Cie SA now owns 37,038 shares of the medical technology company’s stock valued at $10,121,000 after purchasing an additional 6,004 shares in the last quarter. Bank Pictet & Cie Europe AG boosted its stake in shares of Stryker by 25.4% during the 3rd quarter. Bank Pictet & Cie Europe AG now owns 2,195 shares of the medical technology company’s stock valued at $600,000 after purchasing an additional 445 shares in the last quarter. Sonora Investment Management Group LLC bought a new stake in shares of Stryker during the 3rd quarter valued at about $1,496,000. Finally, Duality Advisers LP bought a new stake in shares of Stryker during the 3rd quarter valued at about $683,000. Institutional investors own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.